Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma(†)

BACKGROUND: Aurora kinase A (AURKA) is commonly overexpressed in sarcoma. The inhibition of AURKA by shRNA or by a specific AURKA inhibitor blocks in vitro proliferation of multiple sarcoma subtypes. MLN8237 (alisertib) is a novel oral adenosine triphosphate-competitive AURKA inhibitor. PATIENTS AND...

Full description

Saved in:
Bibliographic Details
Published in:Ann Oncol
Main Authors: Dickson, M. A., Mahoney, M. R., Tap, W. D., D'Angelo, S. P., Keohan, M. L., Van Tine, B. A., Agulnik, M., Horvath, L. E., Nair, J. S., Schwartz, G. K.
Format: Artigo
Language:Inglês
Published: Oxford University Press 2016
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5035789/
https://ncbi.nlm.nih.gov/pubmed/27502708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw281
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items